Hosted on MSN

Larimar Therapeutics Announces Positive Study Results

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Larimar Therapeutics ( (LRMR)) has issued ...
Benzinga.com

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg ...
Yahoo Finance

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Hosted on MSN

Larimar Therapeutics Reports Q2 2025 Financial Results

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Larimar Therapeutics ( (LRMR)) has issued ...
Yahoo Finance

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia

BALA CYNWYD, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Seeking Alpha

Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts

Maintaining a Hold rating on Larimar Therapeutics due to early-stage development of nomlabofusp for Friedreich's ataxia and uncertainty about its functional benefits. The stock has dropped over 50% ...
Nasdaq

Larimar Therapeutics selloff a buying opportunity, says JonesResearch

JonesResearch analyst Catherine Novack reiterates a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target after the company reported initial data from a Phase 2 study for nomlabofusp in ...
FierceBiotech

Larimar's Friedreich's ataxia program free at last from FDA hold

Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had remained in part on the program since 2021. The rare disease biotech can now ...
Nasdaq

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

BALA CYNWYD, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
FierceBiotech

Larimar's limbo finally ends as FDA removes clinical hold on only asset

Larimar Therapeutics held its breath for over a year, but the FDA has finally given the biotech a green light to continue trials of its lead, and only, asset this year. To coincide with its ...
The New York Times

The Bluest Stone

The Dominican Republic wants jewelers to love larimar, the national stone. But authorities shut the mine temporarily after two fatal accidents. The inspiration for Joarla Caridad’s Pool Ring with ...